A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701-Reference-Cited by-同舟云学术

A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701

Published:2022-05 Issue: Volume:166 Page:279-286
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Kobayshi Kazuma^ORCID,Suyama Koichi,Katsuya Hiroo,Izawa Naoki,Uenosono Yoshikazu,Hu Qingjiang,Kusumoto Tetsuya,Otsu Hajime,Orita Hiroyuki,Kawanaka Hirofumi,Shibao Kazunori,Koga Satoshi,Shimokawa Mototsugu,Makiyama Akitaka^ORCID,Saeki Hiroshi,Oki Eiji^ORCID,Baba Hideo,Mori Masaki

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Global cancer statistics 2020;CA: A Canc J Clin,2021

2. The editorial board of the cancer statistics in Japan date of publication: march, 2018,2021

3. Capecitabine and oxaliplatin for advanced esophagogastric cancer;Cunningham;N Engl J Med,2008

4. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group;Cutsem;J Clin Oncol,2006

5. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial;Ochenduszko;Med Oncol,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paracrine activin B-NF-κB signaling shapes an inflammatory tumor microenvironment in gastric cancer via fibroblast reprogramming;Journal of Experimental & Clinical Cancer Research;2023-10-19

2. Eriodictyol Suppresses Gastric Cancer Cells via Inhibition of PI3K/AKT Pathway;Pharmaceuticals;2022-11-27